Graduate School of Medical Science and Engineering, Korea Advanced Institute of Science and Technology (KAIST), Daejeon 34141, Korea.
Mol Cells. 2021 May 31;44(5):356-362. doi: 10.14348/molcells.2021.0032.
An increasing number of studies have revealed an interaction between gut microbiota and tumors. The enrichment of specific bacteria strains in the intestines has been found to modulate tumor growth and influence the mechanisms of tumor treatment. Various bacteria are involved in modulating the effects of chemotherapeutic drugs currently used to treat patients with cancer, and they affect not only gastrointestinal tract tumors but also distant organ tumors. In addition, changes in the gut microbiota are known to be involved in the antitumor immune response as well as the modulation of the intestinal immune system. As a result, the gut microbiota plays an important role in modulating the efficacy of immune checkpoint inhibitors. Therefore, gut microbiota could be considered as an adjuvant treatment option with other cancer treatment or as another marker for predicting treatment response. In this review, we examine how gut microbiota affects cancer treatments.
越来越多的研究揭示了肠道微生物群与肿瘤之间的相互作用。研究发现，肠道中特定细菌菌株的富集可以调节肿瘤生长并影响肿瘤治疗的机制。各种细菌参与调节目前用于治疗癌症患者的化疗药物的作用，它们不仅影响胃肠道肿瘤，还影响远处器官的肿瘤。此外，已知肠道微生物群的变化参与抗肿瘤免疫反应以及肠道免疫系统的调节。因此，肠道微生物群在调节免疫检查点抑制剂的疗效方面起着重要作用。因此，肠道微生物群可以被认为是与其他癌症治疗方法一起作为辅助治疗选择，或者作为预测治疗反应的另一个标志物。在这篇综述中，我们研究了肠道微生物群如何影响癌症治疗。
